Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

J Harrington, Kevin; Burtness, Barbara; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Brana, Irene; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; G M Hughes, Brett; Mesia, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Zamaniah Wan Ishak, Wan; Lin, Jianxin; Gumuscu, Burak; F Swaby, Ramona; Rischin, Danny

doi:10.1200/jco.21.02508

Public

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Feb 1, 2023

NobleIDark:/48914/w1/20260526/FE50BC32Record on NobleID

Authors:

Kevin J Harrington

,

Barbara Burtness

,

Richard Greil

Abstract

PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. METHODS: Patients were randomly as...

Discussions